Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis

Susan Ruth Marengo, Daniel H C Chen, Andrew Evan, Andre J. Sommer, Nicholas T. Stowe, Donald G. Ferguson, Martin I. Resnick, Gregory T. MacLennan

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

It is hypothesized that oxalate plays an active role in calcium oxalate (CaOx) nephrocalcinosis and oxalate driven nephrolithiasis by interacting with the kidney. We developed an adjustable, nonprecursor, continuous infusion model of hyperoxaluria and CaOx nephrocalcinosis to investigate this hypothesis. Minipumps containing PBS or KOx (60-360 μmol/day; n= 5-7/dose) were implanted subcutaneously in male Sprague-Dawley rats on D0 and D6. Rats were killed on D13. Oxalate excretion and CaOx crystalluria were monitored by 20+4 h urine collections. Localization and content of intrarenal crystals were determined on frozen sections using polarization and μFTIR. Oxalate excretion was significantly elevated in all KOx rats (P ≤ 0.005). CaOx crystalluria was most persistent in the 240-360 μmol/day KOx rats, but even 60 μmol/day KOx rats showed sporadic crystalluria. One hundred percent of KOx rats had CaOx nephrocalcinosis as confirmed by μFTIR. Most crystals were localized to the lumens of the corticomedullary collecting ducts. A few crystals are localized just under the papular urothelium. The minipump model is the first model of hyperoxaluria to provide continuous infusion of oxalate. It permits control of the levels of hyperoxaluria, crystalluria and CaOx nephrocalcinosis. The level of sustained hyperoxaluria and CaOx nephrocalcinosis induced by treatment with 360 μmol/day KOx for 13D models the conditions frequently observed in jejunoileal bypass patients. Adjustments in the length of treatment and level of hyperoxaluria may allow this model to also be used to study the oxalate driven CaOx-nephrolithiasis common in patients with hyperoxaluria due to other causes.

Original languageEnglish
Pages (from-to)200-210
Number of pages11
JournalUrological Research
Volume34
Issue number3
DOIs
StatePublished - Jun 2006

Fingerprint

Nephrocalcinosis
Calcium Oxalate
Hyperoxaluria
Oxalates
Fourier Transform Infrared Spectroscopy
Jejunoileal Bypass
Urothelium
Nephrolithiasis
Urine Specimen Collection
Frozen Sections
Sprague Dawley Rats
Kidney
Therapeutics

Keywords

  • Calcium
  • Nephrocalcinosis
  • Nephrolithiasis
  • Oxalate
  • Oxalosis
  • Rat

ASJC Scopus subject areas

  • Urology

Cite this

Marengo, S. R., Chen, D. H. C., Evan, A., Sommer, A. J., Stowe, N. T., Ferguson, D. G., ... MacLennan, G. T. (2006). Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis. Urological Research, 34(3), 200-210. https://doi.org/10.1007/s00240-006-0043-7

Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis. / Marengo, Susan Ruth; Chen, Daniel H C; Evan, Andrew; Sommer, Andre J.; Stowe, Nicholas T.; Ferguson, Donald G.; Resnick, Martin I.; MacLennan, Gregory T.

In: Urological Research, Vol. 34, No. 3, 06.2006, p. 200-210.

Research output: Contribution to journalArticle

Marengo, SR, Chen, DHC, Evan, A, Sommer, AJ, Stowe, NT, Ferguson, DG, Resnick, MI & MacLennan, GT 2006, 'Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis', Urological Research, vol. 34, no. 3, pp. 200-210. https://doi.org/10.1007/s00240-006-0043-7
Marengo, Susan Ruth ; Chen, Daniel H C ; Evan, Andrew ; Sommer, Andre J. ; Stowe, Nicholas T. ; Ferguson, Donald G. ; Resnick, Martin I. ; MacLennan, Gregory T. / Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis. In: Urological Research. 2006 ; Vol. 34, No. 3. pp. 200-210.
@article{dad2d72da1ed482696eb5b76148970cc,
title = "Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis",
abstract = "It is hypothesized that oxalate plays an active role in calcium oxalate (CaOx) nephrocalcinosis and oxalate driven nephrolithiasis by interacting with the kidney. We developed an adjustable, nonprecursor, continuous infusion model of hyperoxaluria and CaOx nephrocalcinosis to investigate this hypothesis. Minipumps containing PBS or KOx (60-360 μmol/day; n= 5-7/dose) were implanted subcutaneously in male Sprague-Dawley rats on D0 and D6. Rats were killed on D13. Oxalate excretion and CaOx crystalluria were monitored by 20+4 h urine collections. Localization and content of intrarenal crystals were determined on frozen sections using polarization and μFTIR. Oxalate excretion was significantly elevated in all KOx rats (P ≤ 0.005). CaOx crystalluria was most persistent in the 240-360 μmol/day KOx rats, but even 60 μmol/day KOx rats showed sporadic crystalluria. One hundred percent of KOx rats had CaOx nephrocalcinosis as confirmed by μFTIR. Most crystals were localized to the lumens of the corticomedullary collecting ducts. A few crystals are localized just under the papular urothelium. The minipump model is the first model of hyperoxaluria to provide continuous infusion of oxalate. It permits control of the levels of hyperoxaluria, crystalluria and CaOx nephrocalcinosis. The level of sustained hyperoxaluria and CaOx nephrocalcinosis induced by treatment with 360 μmol/day KOx for 13D models the conditions frequently observed in jejunoileal bypass patients. Adjustments in the length of treatment and level of hyperoxaluria may allow this model to also be used to study the oxalate driven CaOx-nephrolithiasis common in patients with hyperoxaluria due to other causes.",
keywords = "Calcium, Nephrocalcinosis, Nephrolithiasis, Oxalate, Oxalosis, Rat",
author = "Marengo, {Susan Ruth} and Chen, {Daniel H C} and Andrew Evan and Sommer, {Andre J.} and Stowe, {Nicholas T.} and Ferguson, {Donald G.} and Resnick, {Martin I.} and MacLennan, {Gregory T.}",
year = "2006",
month = "6",
doi = "10.1007/s00240-006-0043-7",
language = "English",
volume = "34",
pages = "200--210",
journal = "Urolithiasis",
issn = "2194-7228",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis

AU - Marengo, Susan Ruth

AU - Chen, Daniel H C

AU - Evan, Andrew

AU - Sommer, Andre J.

AU - Stowe, Nicholas T.

AU - Ferguson, Donald G.

AU - Resnick, Martin I.

AU - MacLennan, Gregory T.

PY - 2006/6

Y1 - 2006/6

N2 - It is hypothesized that oxalate plays an active role in calcium oxalate (CaOx) nephrocalcinosis and oxalate driven nephrolithiasis by interacting with the kidney. We developed an adjustable, nonprecursor, continuous infusion model of hyperoxaluria and CaOx nephrocalcinosis to investigate this hypothesis. Minipumps containing PBS or KOx (60-360 μmol/day; n= 5-7/dose) were implanted subcutaneously in male Sprague-Dawley rats on D0 and D6. Rats were killed on D13. Oxalate excretion and CaOx crystalluria were monitored by 20+4 h urine collections. Localization and content of intrarenal crystals were determined on frozen sections using polarization and μFTIR. Oxalate excretion was significantly elevated in all KOx rats (P ≤ 0.005). CaOx crystalluria was most persistent in the 240-360 μmol/day KOx rats, but even 60 μmol/day KOx rats showed sporadic crystalluria. One hundred percent of KOx rats had CaOx nephrocalcinosis as confirmed by μFTIR. Most crystals were localized to the lumens of the corticomedullary collecting ducts. A few crystals are localized just under the papular urothelium. The minipump model is the first model of hyperoxaluria to provide continuous infusion of oxalate. It permits control of the levels of hyperoxaluria, crystalluria and CaOx nephrocalcinosis. The level of sustained hyperoxaluria and CaOx nephrocalcinosis induced by treatment with 360 μmol/day KOx for 13D models the conditions frequently observed in jejunoileal bypass patients. Adjustments in the length of treatment and level of hyperoxaluria may allow this model to also be used to study the oxalate driven CaOx-nephrolithiasis common in patients with hyperoxaluria due to other causes.

AB - It is hypothesized that oxalate plays an active role in calcium oxalate (CaOx) nephrocalcinosis and oxalate driven nephrolithiasis by interacting with the kidney. We developed an adjustable, nonprecursor, continuous infusion model of hyperoxaluria and CaOx nephrocalcinosis to investigate this hypothesis. Minipumps containing PBS or KOx (60-360 μmol/day; n= 5-7/dose) were implanted subcutaneously in male Sprague-Dawley rats on D0 and D6. Rats were killed on D13. Oxalate excretion and CaOx crystalluria were monitored by 20+4 h urine collections. Localization and content of intrarenal crystals were determined on frozen sections using polarization and μFTIR. Oxalate excretion was significantly elevated in all KOx rats (P ≤ 0.005). CaOx crystalluria was most persistent in the 240-360 μmol/day KOx rats, but even 60 μmol/day KOx rats showed sporadic crystalluria. One hundred percent of KOx rats had CaOx nephrocalcinosis as confirmed by μFTIR. Most crystals were localized to the lumens of the corticomedullary collecting ducts. A few crystals are localized just under the papular urothelium. The minipump model is the first model of hyperoxaluria to provide continuous infusion of oxalate. It permits control of the levels of hyperoxaluria, crystalluria and CaOx nephrocalcinosis. The level of sustained hyperoxaluria and CaOx nephrocalcinosis induced by treatment with 360 μmol/day KOx for 13D models the conditions frequently observed in jejunoileal bypass patients. Adjustments in the length of treatment and level of hyperoxaluria may allow this model to also be used to study the oxalate driven CaOx-nephrolithiasis common in patients with hyperoxaluria due to other causes.

KW - Calcium

KW - Nephrocalcinosis

KW - Nephrolithiasis

KW - Oxalate

KW - Oxalosis

KW - Rat

UR - http://www.scopus.com/inward/record.url?scp=33646731309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646731309&partnerID=8YFLogxK

U2 - 10.1007/s00240-006-0043-7

DO - 10.1007/s00240-006-0043-7

M3 - Article

C2 - 16479391

AN - SCOPUS:33646731309

VL - 34

SP - 200

EP - 210

JO - Urolithiasis

JF - Urolithiasis

SN - 2194-7228

IS - 3

ER -